-+ 0.00%
-+ 0.00%
-+ 0.00%

Decoy Therapeutics says preclinical PK data support once-weekly intranasal dosing for DCOY-CoV program

PUBT·09/29/2026 11:31:18
Listen to the news
Decoy Therapeutics says preclinical PK data support once-weekly intranasal dosing for DCOY-CoV program
  • Decoy Therapeutics released preclinical PK data supporting once-weekly intranasal dosing for lead coronavirus program DCOY-CoV.
  • Single intranasal dose maintained drug concentrations above designed therapeutic levels for up to seven days in nasal mucosa and lung tissue.
  • Extended tissue retention supports use as a prophylactic for high-risk patients, including immunocompromised people and COPD patients.
  • DCOY-CoV targets endemic human coronaviruses, including SARS-CoV-2, using the company’s multi-antiviral design approach.
  • Program is expected to enter clinical trials in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290730PR_NEWS_USPR_____NE58803) on September 29, 2026, and is solely responsible for the information contained therein.